RSS   Newsletter   Contact   Advertise with us
Post Online Media

Amicus Therapeutics appoints Craig A. Wheeler to board

Craig A. WheelerAmicus Therapeutics, Inc., a biopharmaceutical company, announced the election and appointment of Craig A. Wheeler to its board of directors.
Article continues below

READ MORE Amicus Therapeutics appoints Margaret G. McGlynn to board of directors

Mr. Wheeler has extensive experience in leading biopharmaceutical companies to advance a wide range of treatments for serious diseases. He is currently President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also serves on the board of directors.

Mr. Wheeler led Momenta through the launch of its first complex drug products and he has also overseen the company’s growth into a diversified business.

Prior to Momenta, he worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines & Diagnostics).

Prior to joining Chiron, Mr. Wheeler was a senior member of The Boston Consulting Group's health care practice. He also worked for Merck's MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst.

Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals until 2015 when it was acquired by Otsuka Pharmaceuticals.

He also served as GPhA’s Chairman of the Board of Directors from 2014 to February 2016. In 2011 he was an E&Y Entrepreneur of the Year Regional Award winner.

Mr. Wheeler holds a BS and an MS degree in chemical engineering from Cornell University, and an MBA from the Wharton School of the University of Pennsylvania.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy